Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Investigating Bordetella pertussis colonisation and immunity: protocol for an inpatient controlled human infection model.

de Graaf H, Gbesemete D, Gorringe AR, Diavatopoulos DA, Kester KE, Faust SN, Read RC.

BMJ Open. 2017 Oct 11;7(10):e018594. doi: 10.1136/bmjopen-2017-018594.

2.

Acquisition and loss of virulence-associated factors during genome evolution and speciation in three clades of Bordetella species.

Linz B, Ivanov YV, Preston A, Brinkac L, Parkhill J, Kim M, Harris SR, Goodfield LL, Fry NK, Gorringe AR, Nicholson TL, Register KB, Losada L, Harvill ET.

BMC Genomics. 2016 Sep 30;17(1):767.

3.

Structural, Functional, and Immunogenic Insights on Cu,Zn Superoxide Dismutase Pathogenic Virulence Factors from Neisseria meningitidis and Brucella abortus.

Pratt AJ, DiDonato M, Shin DS, Cabelli DE, Bruns CK, Belzer CA, Gorringe AR, Langford PR, Tabatabai LB, Kroll JS, Tainer JA, Getzoff ED.

J Bacteriol. 2015 Dec;197(24):3834-47. doi: 10.1128/JB.00343-15. Epub 2015 Oct 12.

4.

Nasal Inoculation of the Commensal Neisseria lactamica Inhibits Carriage of Neisseria meningitidis by Young Adults: A Controlled Human Infection Study.

Deasy AM, Guccione E, Dale AP, Andrews N, Evans CM, Bennett JS, Bratcher HB, Maiden MC, Gorringe AR, Read RC.

Clin Infect Dis. 2015 May 15;60(10):1512-20. doi: 10.1093/cid/civ098. Epub 2015 Mar 25.

PMID:
25814628
5.

Genomic analysis of isolates from the United Kingdom 2012 pertussis outbreak reveals that vaccine antigen genes are unusually fast evolving.

Sealey KL, Harris SR, Fry NK, Hurst LD, Gorringe AR, Parkhill J, Preston A.

J Infect Dis. 2015 Jul 15;212(2):294-301. doi: 10.1093/infdis/jiu665. Epub 2014 Dec 8.

PMID:
25489002
6.

Bordetella pertussis fimbriae (Fim): relevance for vaccines.

Gorringe AR, Vaughan TE.

Expert Rev Vaccines. 2014 Oct;13(10):1205-14. doi: 10.1586/14760584.2014.930667. Epub 2014 Aug 8. Review.

PMID:
25102891
7.

Plasticity of fimbrial genotype and serotype within populations of Bordetella pertussis: analysis by paired flow cytometry and genome sequencing.

Vaughan TE, Pratt CB, Sealey K, Preston A, Fry NK, Gorringe AR.

Microbiology. 2014 Sep;160(Pt 9):2030-2044. doi: 10.1099/mic.0.079251-0. Epub 2014 Jul 15.

PMID:
25028460
8.

Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007.

Hallander H, Advani A, Alexander F, Gustafsson L, Ljungman M, Pratt C, Hall I, Gorringe AR.

Clin Vaccine Immunol. 2014 Feb;21(2):165-73. doi: 10.1128/CVI.00641-13. Epub 2013 Dec 4.

9.

Antibody responses to individual Bordetella pertussis fimbrial antigen Fim2 or Fim3 following immunization with the five-component acellular pertussis vaccine or to pertussis disease.

Alexander F, Matheson M, Fry NK, Labram B, Gorringe AR.

Clin Vaccine Immunol. 2012 Nov;19(11):1776-83. doi: 10.1128/CVI.00355-12. Epub 2012 Sep 5.

10.

Bexsero: a multicomponent vaccine for prevention of meningococcal disease.

Gorringe AR, Pajón R.

Hum Vaccin Immunother. 2012 Feb;8(2):174-83. doi: 10.4161/hv.18500. Epub 2012 Feb 1.

PMID:
22426368
11.

Structural basis for iron piracy by pathogenic Neisseria.

Noinaj N, Easley NC, Oke M, Mizuno N, Gumbart J, Boura E, Steere AN, Zak O, Aisen P, Tajkhorshid E, Evans RW, Gorringe AR, Mason AB, Steven AC, Buchanan SK.

Nature. 2012 Feb 12;483(7387):53-8. doi: 10.1038/nature10823.

12.

Induction of immune responses by purified outer membrane protein complexes from Neisseria meningitidis.

Marzoa J, Sánchez S, Costoya L, Diéguez-Casal E, Freixeiro P, Brookes C, Allen L, Taylor S, Gorringe AR, Ferreirós CM, Criado MT.

Vaccine. 2012 Mar 16;30(13):2387-95. doi: 10.1016/j.vaccine.2011.08.123. Epub 2011 Sep 10.

PMID:
21911024
13.

Cooperative role for tetraspanins in adhesin-mediated attachment of bacterial species to human epithelial cells.

Green LR, Monk PN, Partridge LJ, Morris P, Gorringe AR, Read RC.

Infect Immun. 2011 Jun;79(6):2241-9. doi: 10.1128/IAI.01354-10. Epub 2011 Apr 4.

14.

Nasopharyngeal colonization by Neisseria lactamica and induction of protective immunity against Neisseria meningitidis.

Evans CM, Pratt CB, Matheson M, Vaughan TE, Findlow J, Borrow R, Gorringe AR, Read RC.

Clin Infect Dis. 2011 Jan 1;52(1):70-7. doi: 10.1093/cid/ciq065.

PMID:
21148522
15.
16.

Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.

Gorringe AR, Taylor S, Brookes C, Matheson M, Finney M, Kerr M, Hudson M, Findlow J, Borrow R, Andrews N, Kafatos G, Evans CM, Read RC.

Clin Vaccine Immunol. 2009 Aug;16(8):1113-20. doi: 10.1128/CVI.00118-09. Epub 2009 Jun 24.

17.

A Neisseria meningitidis NMB1966 mutant is impaired for invasion of respiratory epithelial cells, survival in human blood and for virulence in vivo.

Li MS, Chow NY, Sinha S, Halliwell D, Finney M, Gorringe AR, Watson MW, Kroll JS, Langford PR, Webb SA.

Med Microbiol Immunol. 2009 Feb;198(1):57-67. doi: 10.1007/s00430-008-0105-2. Epub 2008 Dec 3.

PMID:
19050914
18.

Neisserial outer membrane vesicles bind the coinhibitory receptor carcinoembryonic antigen-related cellular adhesion molecule 1 and suppress CD4+ T lymphocyte function.

Lee HS, Boulton IC, Reddin K, Wong H, Halliwell D, Mandelboim O, Gorringe AR, Gray-Owen SD.

Infect Immun. 2007 Sep;75(9):4449-55. Epub 2007 Jul 9.

19.

Proteomic analysis of Neisseria lactamica and N eisseria meningitidis outer membrane vesicle vaccine antigens.

Vaughan TE, Skipp PJ, O'Connor CD, Hudson MJ, Vipond R, Elmore MJ, Gorringe AR.

Vaccine. 2006 Jun 19;24(25):5277-93. Epub 2006 Mar 23.

PMID:
16682101
20.

Can Neisseria lactamica antigens provide an effective vaccine to prevent meningococcal disease?

Gorringe AR.

Expert Rev Vaccines. 2005 Jun;4(3):373-9. Review.

PMID:
16026250
21.

Homology modelling of transferrin-binding protein A from Neisseria meningitidis.

Oakhill JS, Sutton BJ, Gorringe AR, Evans RW.

Protein Eng Des Sel. 2005 May;18(5):221-8. Epub 2005 Apr 8.

PMID:
15820975
22.

Experimental disease models for the assessment of meningococcal vaccines.

Gorringe AR, Reddin KM, Funnell SG, Johansson L, Rytkönen A, Jonsson AB.

Vaccine. 2005 Mar 18;23(17-18):2214-7.

PMID:
15755598
23.

Meningococcal transferrin-binding proteins A and B show cooperation in their binding kinetics for human transferrin.

Stokes RH, Oakhill JS, Joannou CL, Gorringe AR, Evans RW.

Infect Immun. 2005 Feb;73(2):944-52.

24.

Expression of heterologous antigens in commensal Neisseria spp.: preservation of conformational epitopes with vaccine potential.

O'dwyer CA, Reddin K, Martin D, Taylor SC, Gorringe AR, Hudson MJ, Brodeur BR, Langford PR, Kroll JS.

Infect Immun. 2004 Nov;72(11):6511-8.

25.

The plug domain of a neisserial TonB-dependent transporter retains structural integrity in the absence of its transmembrane beta-barrel.

Oke M, Sarra R, Ghirlando R, Farnaud S, Gorringe AR, Evans RW, Buchanan SK.

FEBS Lett. 2004 Apr 30;564(3):294-300.

26.

Infection with an avirulent phoP mutant of Neisseria meningitidis confers broad cross-reactive immunity.

Newcombe J, Eales-Reynolds LJ, Wootton L, Gorringe AR, Funnell SG, Taylor SC, McFadden JJ.

Infect Immun. 2004 Jan;72(1):338-44.

27.

Neisseria lactamica protects against experimental meningococcal infection.

Oliver KJ, Reddin KM, Bracegirdle P, Hudson MJ, Borrow R, Feavers IM, Robinson A, Cartwright K, Gorringe AR.

Infect Immun. 2002 Jul;70(7):3621-6.

28.

Expression and purification of functional recombinant meningococcal transferrin-binding protein A.

Oakhill JS, Joannou CL, Buchanan SK, Gorringe AR, Evans RW.

Biochem J. 2002 Jun 15;364(Pt 3):613-6.

29.

Bordetella pertussis fimbriae are effective carrier proteins in Neisseria meningitidis serogroup C conjugate vaccines.

Reddin KM, Crowley-Luke A, Clark SO, Vincent PJ, Gorringe AR, Hudson MJ, Robinson A.

FEMS Immunol Med Microbiol. 2001 Aug;31(2):153-62.

30.

Generation and characterization of a PhoP homologue mutant of Neisseria meningitidis.

Johnson CR, Newcombe J, Thorne S, Borde HA, Eales-Reynolds LJ, Gorringe AR, Funnell SG, McFadden JJ.

Mol Microbiol. 2001 Mar;39(5):1345-55.

31.

Animal models for meningococcal disease.

Gorringe AR, Reddin KM, Voet P, Poolman JT.

Methods Mol Med. 2001;66:241-54. doi: 10.1385/1-59259-148-5:241.

PMID:
21336759
32.

Human opsonins induced during meningococcal disease recognize transferrin binding protein complexes.

Lehmann AK, Gorringe AR, Reddin KM, West K, Smith I, Halstensen A.

Infect Immun. 1999 Dec;67(12):6526-32.

33.

Analysis of the human Ig isotype response to lactoferrin binding protein A from Neisseria meningitidis.

Johnson AS, Gorringe AR, Mackinnon FG, Fox AJ, Borrow R, Robinson A.

FEMS Immunol Med Microbiol. 1999 Sep;25(4):349-54.

34.

A dynamic model of the meningococcal transferrin receptor.

Boulton IC, Gorringe AR, Shergill JK, Joannou CL, Evans RW.

J Theor Biol. 1999 Jun 21;198(4):497-505.

PMID:
10373350
35.

Purified meningococcal transferrin-binding protein B interacts with a secondary, strain-specific, binding site in the N-terminal lobe of human transferrin.

Boulton IC, Gorringe AR, Gorinsky B, Retzer MD, Schryvers AB, Joannou CL, Evans RW.

Biochem J. 1999 Apr 1;339 ( Pt 1):143-9.

36.

Transferrin-binding protein B isolated from Neisseria meningitidis discriminates between apo and diferric human transferrin.

Boulton IC, Gorringe AR, Allison N, Robinson A, Gorinsky B, Joannou CL, Evans RW.

Biochem J. 1998 Aug 15;334 ( Pt 1):269-73.

37.

Differential binding of apo and holo human transferrin to meningococci and co-localisation of the transferrin-binding proteins (TbpA and TbpB).

Powell NB, Bishop K, Palmer HM, Ala'Aldeen DA, Gorringe AR, Borriello SP.

J Med Microbiol. 1998 Mar;47(3):257-64.

PMID:
9511831
38.

Periplasmic superoxide dismutase in meningococcal pathogenicity.

Wilks KE, Dunn KL, Farrant JL, Reddin KM, Gorringe AR, Langford PR, Kroll JS.

Infect Immun. 1998 Jan;66(1):213-7.

39.

Analysis of the human Ig isotype response to individual transferrin binding proteins A and B from Neisseria meningitidis.

Johnson AS, Gorringe AR, Fox AJ, Borrow R, Robinson A.

FEMS Immunol Med Microbiol. 1997 Oct;19(2):159-67.

40.

Characterisation of the meningococcal transferrin binding protein complex by photon correlation spectroscopy.

Boulton IC, Gorringe AR, Carr RJ, Gorinsky B, Joannou CL, Evans RW.

FEBS Lett. 1997 Sep 8;414(2):409-13. Erratum in: FEBS Lett 1997 Nov 24;418(1-2):228.

41.

Human antibody response to meningococcal transferrin binding proteins: evidence for vaccine potential.

Gorringe AR, Borrow R, Fox AJ, Robinson A.

Vaccine. 1995 Sep;13(13):1207-12.

PMID:
8578805
42.

Immune responses in humans and animals to meningococcal transferrin-binding proteins: implications for vaccine design.

Ala'Aldeen DA, Stevenson P, Griffiths E, Gorringe AR, Irons LI, Robinson A, Hyde S, Borriello SP.

Infect Immun. 1994 Jul;62(7):2984-90.

43.

Demonstration of lipooligosaccharide immunotype and capsule as virulence factors for Neisseria meningitidis using an infant mouse intranasal infection model.

Mackinnon FG, Borrow R, Gorringe AR, Fox AJ, Jones DM, Robinson A.

Microb Pathog. 1993 Nov;15(5):359-66.

PMID:
7912406
44.

Intranasal infection of infant mice with Neisseria meningitidis.

Mackinnon FG, Gorringe AR, Funnell SG, Robinson A.

Microb Pathog. 1992 Jun;12(6):415-20.

PMID:
1522796
45.

Growth and siderophore production by Bordetella pertussis under iron-restricted conditions.

Gorringe AR, Woods G, Robinson A.

FEMS Microbiol Lett. 1990 Jan 1;54(1-3):101-5.

PMID:
2138989
46.

Serospecific protection of mice against intranasal infection with Bordetella pertussis.

Robinson A, Gorringe AR, Funnell SG, Fernandez M.

Vaccine. 1989 Aug;7(4):321-4.

PMID:
2573215
47.

Agglutinogens and fimbriae of Bordetella pertussis.

Ashworth LA, Robinson A, Funnell S, Gorringe AR, Irons LI, Seabrook RN.

Tokai J Exp Clin Med. 1988;13 Suppl:203-10.

PMID:
2908520

Supplemental Content

Loading ...
Support Center